Question explored with the scientific record
Is the flu vaccine safe and effective?
The flu vaccine offers modest, season-dependent protection against lab-confirmed influenza, but the evidence for preventing serious outcomes like hospitalization is weaker and more inconsistent than most people are told.
The retrieved studies show vaccine effectiveness (VE) against lab-confirmed influenza typically ranges from about 30% to 50%, with wide variation by season, age, and circulating strain [1][2][4][6][7][8][9]. In a bad year, like 2014/15 in Stockholm, VE in adults over 65 dropped to 18% [19]. Against the A(H3N2) strain, which tends to hit older adults hardest, VE is often negligible: one pooled analysis found just 14% effectiveness in people 65 and older [15], and a 2021/22 season study found no significant protection at all in that age group [18].
The safety data is dominated by passive surveillance systems like VAERS, which detect only a tiny fraction of adverse events by design [11][12]. The best-documented serious risk is Guillain-Barré syndrome (GBS). The 1976 swine flu vaccine caused about 10 extra GBS cases per million doses [14]. For modern seasonal vaccines, the risk is much smaller but still measurable: about 1 extra case per million vaccinations, based on 1992-94 data [13][14]. That means for every million older adults vaccinated, roughly 1 will get GBS from the shot, while the vaccine may prevent a handful of hospitalizations—but the evidence for those hospitalizations reductions is surprisingly weak [16][17].
| Group | VE against lab-confirmed flu | VE against hospitalization | GBS risk per million doses |
|---|---|---|---|
| Children 2-6 (LAIV) | 50% [5] | 50% [5] | Not quantified in these records |
| Adults 18-64 | 40-60% [1][6][7] | 71% (one small study) [3] | ~1 [13][14] |
| Adults 65+ | 14-49% [15][19] | Often not significant [18] | ~1 [13][14] |
The evidence base has serious structural problems. Nearly all studies are observational test-negative designs, not randomized trials [1][2][4][5][6][7][8][9]. The one randomized trial in the retrieval, in COPD patients, showed 76% effectiveness against influenza-related illness, but that was a single small study in a specific high-risk group [10]. No study in the retrieval compared vaccinated to truly unvaccinated people over the long term for all-cause mortality or serious adverse events. The systematic review of healthcare utilization in older adults found the evidence "low quality" and too heterogeneous to draw conclusions [16].
My call: the flu vaccine provides modest, unreliable protection against lab-confirmed influenza, with a very small risk of GBS. The claim that it prevents hospitalization or death in older adults is not well supported by the evidence retrieved here. Confidence: moderate for the effectiveness range, low for the claim of preventing serious outcomes.
Sources used 19
-
Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010–2016
A multicountry retrospective test-negative design study (PREVENT) across 2010–2016 estimated influenza vaccine effectiveness against laboratory-confirmed influenza–associated hospitalizations in pregnant women, finding an overall adjusted VE of 40% with substantial variation by …
DOI: 10.1093/cid/ciy737 -
Influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children in England in the 2015–2016 influenza season – a test-negative case–control study
In 2015-2016 England, influenza vaccination in vaccine-eligible children 2-16 years provided 33.4% adjusted effectiveness against laboratory-confirmed influenza hospitalisation, with LAIV at 41.9% and IIV at 28.8%.
DOI: 10.1017/s0950268819000876 -
Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Adults, 2011–2012 Influenza Season
During the 2011-2012 influenza season, vaccination was 71.4% effective (95% CI, 17.1%-94.9%) in preventing laboratory-confirmed influenza-associated hospitalizations among adults with acute respiratory illness.
DOI: 10.1093/cid/cit124 -
Effectiveness of trivalent and monovalent influenza vaccines against laboratory-confirmed influenza infection in persons with medically attended influenza-like illness in Bavaria, Germany, 2010/2011 season
Trivalent seasonal influenza vaccines were about 70% effective against laboratory-confirmed influenza among medically attended ILI patients in Bavaria during 2010/2011, while monovalent vaccines from 2009/2010 showed limited protection against A(H1N1)pdm09.
DOI: 10.1017/s0950268812002282 -
Live‐attenuated influenza vaccine effectiveness against hospitalization in children aged 2–6 years, the first three seasons of the childhood influenza vaccination program in England, 2013/14–2015/16
The first three seasons of England's childhood LAIV vaccination program were associated with 50.1% adjusted vaccine effectiveness against laboratory-confirmed influenza hospitalization in 2-6-year-olds, with positive estimates by age group and influenza type, though risk-stratif…
DOI: 10.1111/irv.12990 -
Influenza Vaccine Effectiveness Among Children for the 2017–2018 Season
Influenza vaccine was 52% effective against laboratory-confirmed influenza in children during 2017-2018, was similar against influenza A and B, was not worsened by prior-season vaccination, and showed no evidence of intraseasonal waning.
DOI: 10.1093/jpids/piz077 -
Estimating vaccine effectiveness in preventing laboratory‐confirmed influenza in outpatient settings in South Africa, 2015
In a South African outpatient test-negative case-control study during the 2015 influenza season, trivalent influenza vaccine effectiveness was 46.2% against any laboratory-confirmed influenza and 53.5% against influenza A(H1N1)pdm09, with low overall vaccine coverage of 3.2%.
DOI: 10.1111/irv.12436 -
Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds – a nationwide cohort study Finland, influenza season 2015/16
A nationwide register-based cohort study in Finland during the 2015/16 influenza season found moderate effectiveness of both quadrivalent live attenuated influenza vaccine (VE 51%, 95% CI 28-66%) and trivalent inactivated influenza vaccine (VE 61%, 95% CI 31-78%) against laborat…
DOI: 10.2807/1560-7917.es.2016.21.38.30346 -
Effects of previous episodes of influenza and vaccination in preventing laboratory-confirmed influenza in Navarre, Spain, 2013/14 season
In a test-negative case-control study in Navarre, Spain, during the 2013/14 influenza season, previous influenza episodes conferred high subtype-specific protection against laboratory-confirmed influenza (63% against A(H1N1)pdm09 and 65% against A(H3N2)), while the trivalent inf…
DOI: 10.2807/1560-7917.es.2016.21.22.30243 -
Acute Respiratory Illness in Patients With COPD and the Effectiveness of Influenza Vaccination
This randomized controlled study investigates the effectiveness of influenza vaccination in preventing influenza-related acute respiratory illness (ARI) in patients with chronic obstructive pulmonary disease (COPD), demonstrating a significant reduction in influenza-related ARI …
DOI: 10.1378/chest.125.6.2011 -
Adverse Events Reported Following Live, Cold-Adapted, Intranasal Influenza Vaccine
This study analyzes US VAERS data from 2003–2005 to characterize adverse events reported after intranasal live, attenuated influenza vaccine (LAIV-T), finding 460 reports (including 40 serious) among about 2.5 million vaccinees, with rare events such as possible anaphylaxis and …
DOI: 10.1001/jama.294.21.2720 -
H1N1 vaccine safety monitoring: beyond background rates
This commentary emphasizes that rare adverse events after mass vaccination can occur by chance and must be interpreted against established background disease rates, outlining limitations and safety-monitoring approaches in vaccine safety.
DOI: 10.1016/s0140-6736(09)61917-6 -
The Guillain–Barré Syndrome and the 1992–1993 and 1993–1994 Influenza Vaccines
In four U.S. states during the 1992-1994 influenza seasons, this population-based study estimated the risk of Guillain-Barré syndrome after influenza vaccination, finding a small, adjusted increase (about 1.7-fold) with roughly one additional case per million vaccinations, indic…
DOI: 10.1056/NEJM199812173392501 -
Guillain-Barré Syndrome and Vaccination: Usually Unrelated
A narrative review of epidemiological data on Guillain-Barré syndrome (GBS) and vaccines concludes that GBS is usually triggered by antecedent infections rather than vaccination; clear causal associations were limited to the obsolete neural-tissue rabies vaccine and the 1976 swi…
DOI: 10.1177/001857870003500214 -
Influenza vaccine effectiveness in older adults compared with younger adults over five seasons
This study conducted a pooled analysis of influenza vaccine effectiveness over five seasons, comparing older adults (aged 65 years and above) with younger adults (aged 18-49 years), and found no significant differences in vaccine effectiveness between the two groups across vario…
DOI: 10.1016/j.vaccine.2018.01.045 -
Impact of influenza vaccination on healthcare utilization – A systematic review
A systematic review evaluating the impact of seasonal influenza vaccination on healthcare utilization in older adults (65+), finding modest protection for outpatient visits but substantial heterogeneity and overall low-quality evidence that prevents a definitive conclusion about…
DOI: 10.1016/j.vaccine.2019.04.051 -
Influenza Vaccination in Young Children Reduces Influenza‐Associated Hospitalizations in Older Adults, 2002–2006
State-level influenza vaccination coverage in young children was associated with lower pneumonia-and-influenza hospitalization rate acceleration in U.S. adults aged 65 and older during 2002-2006, whereas vaccination coverage in older adults was not significantly associated with …
DOI: 10.1111/j.1532-5415.2010.03271.x -
Effectiveness of influenza vaccination in preventing influenza in primary care, Navarre, Spain, 2021/22
In Navarre, Spain, in 2021/22, influenza vaccine effectiveness against A(H3N2) was 39% (95% CI: 16 to 55) among all ages for current-season vaccination, 37% in the target population, and not significant in people older than 65 years.
DOI: 10.2807/1560-7917.es.2022.27.26.2200488 -
Real-time real-world analysis of seasonal influenza vaccine effectiveness: method development and assessment of a population-based cohort in Stockholm County, Sweden, seasons 2011/12 to 2014/15
Seasonal influenza vaccine effectiveness in Stockholm varied by season and age, with lower protection in 2014/15, no demonstrated effect against non-hospitalised pneumonia, and no healthy-vaccinee bias in pre-season analyses.
DOI: 10.2807/1560-7917.es.2016.21.43.30381